These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9039130)

  • 1. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1-R mRNA antisense.
    Phillips MI; Mohuczy-Dominiak D; Coffey M; Galli SM; Kimura B; Wu P; Zelles T
    Hypertension; 1997 Jan; 29(1 Pt 2):374-80. PubMed ID: 9039130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense inhibition of AT1 receptor in vascular smooth muscle cells using adeno-associated virus-based vector.
    Mohuczy D; Gelband CH; Phillips MI
    Hypertension; 1999 Jan; 33(1 Pt 2):354-9. PubMed ID: 9931129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension.
    Phillips MI
    Hypertension; 1997 Jan; 29(1 Pt 2):177-87. PubMed ID: 9039099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant adeno-associated virus-mediated delivery of antisense angiotensin II receptor 1 gene attenuates hypertension development.
    Li XG; Yan JT; Xu XZ; Wang JN; Cheng LM; Wang T; Zuo P; Wang DW
    Acta Pharmacol Sin; 2007 Nov; 28(11):1737-45. PubMed ID: 17959024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension.
    Tang X; Mohuczy D; Zhang YC; Kimura B; Galli SM; Phillips MI
    Am J Physiol; 1999 Dec; 277(6):H2392-9. PubMed ID: 10600860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatic gene therapy for hypertension.
    Phillips MI
    Braz J Med Biol Res; 2000 Jun; 33(6):715-21. PubMed ID: 10829100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term inhibition of the central alpha(2B)-adrenergic receptor gene via recombinant AAV-delivered antisense in hypertensive rats.
    Shenouda SM; Johns C; Kintsurashvili E; Gavras I; Gavras H
    Am J Hypertens; 2006 Nov; 19(11):1135-43. PubMed ID: 17070424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy for hypertension: sense and antisense strategies.
    Phillips MI
    Expert Opin Biol Ther; 2001 Jul; 1(4):655-62. PubMed ID: 11727501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term modifications of blood pressure in normotensive and spontaneously hypertensive rats by gene delivery of rAAV-mediated cytochrome P450 arachidonic acid hydroxylase.
    Zhang F; Chen CL; Qian JQ; Yan JT; Cianflone K; Xiao X; Wang DW
    Cell Res; 2005 Sep; 15(9):717-24. PubMed ID: 16212878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of inhibition of hypertension by antisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneously hypertensive rats.
    Gyurko R; Tran D; Phillips MI
    Am J Hypertens; 1997 May; 10(5 Pt 2):56S-62S. PubMed ID: 9160782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of antisense DNA by vectors for prolonged effects in vitro and in vivo.
    Mohuczy D; Tang X; Phillips MI
    Methods Enzymol; 2000; 314():32-51. PubMed ID: 10565003
    [No Abstract]   [Full Text] [Related]  

  • 12. Attenuation of hypertension by systemic delivery of retroviral vector containing type I angiotensin II receptor antisense cDNA.
    Reaves PY; Wang HW; Katovich MJ; Gelband CH; Raizada MK
    Methods; 2000 Nov; 22(3):211-8. PubMed ID: 11071816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy.
    Pachori AS; Numan MT; Ferrario CM; Diz DM; Raizada MK; Katovich MJ
    Hypertension; 2002 May; 39(5):969-75. PubMed ID: 12019278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of cold-induced hypertension by antisense oligodeoxynucleotides to angiotensinogen mRNA and AT1-receptor mRNA in brain and blood.
    Peng JF; Kimura B; Fregly MJ; Phillips MI
    Hypertension; 1998 Jun; 31(6):1317-23. PubMed ID: 9622148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element.
    Haberman RP; McCown TJ; Samulski RJ
    J Virol; 2000 Sep; 74(18):8732-9. PubMed ID: 10954575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense.
    Kimura B; Mohuczy D; Tang X; Phillips MI
    Hypertension; 2001 Feb; 37(2 Pt 2):376-80. PubMed ID: 11230303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant adeno-associated virus-mediated kallikrein gene therapy reduces hypertension and attenuates its cardiovascular injuries.
    Wang T; Li H; Zhao C; Chen C; Li J; Chao J; Chao L; Xiao X; Wang DW
    Gene Ther; 2004 Sep; 11(17):1342-50. PubMed ID: 15175642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfection-free and scalable recombinant AAV vector production using HSV/AAV hybrids.
    Booth MJ; Mistry A; Li X; Thrasher A; Coffin RS
    Gene Ther; 2004 May; 11(10):829-37. PubMed ID: 14985784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for hypertension: antisense inhibition with adeno-associated viral vector delivery targeting angiotensin II type 1-receptor messenger ribonucleic acid.
    Phillips MI
    Am J Cardiol; 1998 Nov; 82(10A):60S-62S. PubMed ID: 9860363
    [No Abstract]   [Full Text] [Related]  

  • 20. Construction of recombinant adeno-associated virus vector containing the rat preproinsulin II gene.
    Peng L; Sidner RA; Bochan MR; Burton MM; Cooper ST; Jindal RM
    J Surg Res; 1997 Apr; 69(1):193-8. PubMed ID: 9202669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.